Dr Lal Pathlabs

Is Dr Lal Pathlabs overvalued or undervalued?

As of March 21, 2024, Dr. Lal Pathlabs is considered very expensive and overvalued with a PE ratio of 48.96, despite being more attractive than some competitors like Max Healthcare and Apollo Hospitals, but its growth potential is questionable given a PEG ratio of 1.36 and a low dividend yield of 1.05%.

As of 21 March 2024, the valuation grade for Dr. Lal Pathlabs has moved from expensive to very expensive, indicating a significant shift in its market positioning. The company is currently deemed overvalued. Key ratios include a PE ratio of 48.96, an EV to EBITDA of 32.84, and a Price to Book Value of 10.98, all of which suggest a premium valuation compared to its peers.<BR><BR>In comparison, Max Healthcare has a PE ratio of 100.29, while Apollo Hospitals stands at 69.03, illustrating that Dr. Lal Pathlabs, despite its high valuation, is still more attractive than some competitors. However, with a PEG ratio of 1.36 and a dividend yield of only 1.05%, the stock's growth potential does not justify its current price. Recent performance shows that while Dr. Lal Pathlabs has outperformed the Sensex over the past week and month, it lags behind in the year-to-date and one-year returns, reinforcing the notion that it may be overvalued in the current market context.

how big is Dr Lal Pathlabs?

As of Jun 06, Dr Lal Pathlabs Ltd has a market capitalization of 23,827.41 Cr, with recent net sales of 2,461.40 Cr and net profit of 487.10 Cr for the latest four quarters.

Market Cap: As of Jun 06, Dr Lal Pathlabs Ltd has a market capitalization of 23,827.41 Cr, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Dr Lal Pathlabs reported a sum of Net Sales of 2,461.40 Cr and a sum of Net Profit of 487.10 Cr. This data is consolidated.<BR><BR>Balance Sheet Snapshot: This is consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 1,849.28 Cr, while the Total Assets amount to 2,411.10 Cr.

What does Dr Lal Pathlabs do?

Dr. Lal PathLabs Ltd is a healthcare services company specializing in laboratory testing and diagnostic services, with a market cap of Rs 23,900 Cr and a net profit of 155 Cr for the quarter ending March 2025. The company was founded in 1995 and transitioned to a public limited company in 2015.

Overview: <BR>Dr. Lal PathLabs Ltd is a healthcare services company operating in the large-cap market segment, primarily engaged in laboratory testing and diagnostic services.<BR><BR>History: <BR>Dr. Lal PathLabs Ltd was incorporated as a Private Limited Company on February 14, 1995, in Delhi. It transitioned to a Public Limited Company and changed its name on August 19, 2015. The most recent quarterly results report net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 603 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 155 Cr (Quarterly Results - Mar 2025) <BR>- Market cap: Rs 23,900 Cr (Large Cap) <BR><BR>Key Metrics: <BR>- P/E: 49.00 <BR>- Industry P/E: 54 <BR>- Dividend Yield: 0.84% <BR>- Debt Equity: -0.46 <BR>- Return on Equity: 22.42% <BR>- Price to Book: 11.00 <BR><BR>Contact Details: <BR>Address: E-2 Block Sector 18, Rohini New Delhi New Delhi : 110085 <BR>Tel: 91-011-3024 4149 <BR>Email: cs@lalpathlabs.com <BR>Website: http://www.lalpathlabs.com

When is the next results date for Dr Lal Pathlabs?

No Upcoming Board Meetings

Who are the peers of the Dr Lal Pathlabs?

Dr Lal Pathlabs' peers include Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Health, Suven Life Sciences, Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, and Tarsons Products. Management risk varies from excellent to below average, with growth and capital structure generally rated as good to excellent, while Suven Life Sciences leads in 1-year returns at 118.45%, and Dr Lal Pathlabs has a modest return of 0.15%.

Peers: The peers of Dr Lal Pathlabs are Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Suven Life Scie., Thyrocare Tech., Krsnaa Diagnost., Laxmi Dental, and Tarsons Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, Laxmi Dental, and Thyrocare Tech., while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, and Suven Life Scie. Average management risk is present at Krsnaa Diagnost., and Below Average management risk is noted for Suven Life Scie. Growth is Below Average for Dr Lal Pathlabs, Syngene Intl., Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., and Krsnaa Diagnost., while Average growth is seen at Poly Medicure, Indegene, and the rest. Good growth is observed at Laxmi Dental. Capital Structure is Excellent for Dr Lal Pathlabs, Syngene Intl., Poly Medicure, Indegene, Vijaya Diagnost., Metropolis Healt, Thyrocare Tech., Krsnaa Diagnost., and the rest, while Good capital structure is noted for Laxmi Dental.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 118.45%, while the peer with the lowest is Tarsons Products at -23.12%. Dr Lal Pathlabs has a 1-year return of 0.15%, which is significantly lower than Suven Life Scie. and higher than Tarsons Products. Additionally, Metropolis Healt and Suven Life Scie. have negative six-month returns.

Who are in the management team of Dr Lal Pathlabs?

As of March 2023, the management team of Dr Lal Pathlabs includes Arvind Lal (Chairman & Executive Director), Vandana Lal (Executive Director), Om Prakash Manchanda (Managing Director), and several independent and non-executive directors, totaling 14 members who guide the company's governance and strategy.

As of March 2023, the management team of Dr Lal Pathlabs includes the following individuals:<BR><BR>1. Arvind Lal - Chairman & Executive Director<BR>2. Vandana Lal - Executive Director<BR>3. Om Prakash Manchanda - Executive Director & Managing Director<BR>4. Archana Lal Erdmann - Non-Executive Director<BR>5. Rahul Sharma - Non-Executive Director<BR>6. Anoop Mahendra Singh - Independent Director<BR>7. Harneet Singh Chandhoke - Independent Director<BR>8. Sunil Varma - Lead Independent Director<BR>9. Saurabh Srivastava - Independent Director<BR>10. Somya Satsangi - Independent Director<BR>11. Rohit Bhasin - Independent Director<BR>12. Arun Duggal - Independent Director<BR>13. Gurinder Singh Kalra - Independent Non-Executive Director<BR>14. Rajit Mehta - Independent Non-Executive Director<BR><BR>This team encompasses a mix of executive, non-executive, and independent directors, contributing to the governance and strategic direction of the company.

Who are the top shareholders of the Dr Lal Pathlabs?

The top shareholders of Dr Lal Pathlabs include Arvind Lal with 30.8%, foreign institutional investors holding 23.91%, mutual funds at 12.84%, and Invesco Oppenheimer International Growth Fund as the largest public shareholder with 3.52%. Individual investors own a total of 4.11%.

The top shareholders of Dr Lal Pathlabs include the promoters, with Arvind Lal being the individual with the highest holding at 30.8%. Additionally, institutional investors play a significant role, with foreign institutional investors (FIIs) holding 23.91% through 326 different entities. Mutual funds are represented by 26 schemes, accounting for 12.84% of the shares. The highest public shareholder is Invesco Oppenheimer International Growth Fund, which holds 3.52%. Individual investors collectively own 4.11% of the company.

How has been the historical performance of Dr Lal Pathlabs?

Dr Lal Pathlabs has exhibited consistent growth in net sales and profits, with net sales increasing from ₹1,203.40 Cr in March 2019 to ₹2,461.40 Cr in March 2025, and profit after tax rising from ₹200.50 Cr to ₹492.20 Cr during the same period. The company's earnings per share improved from 23.91 to 58.27, reflecting strong overall performance.

Answer:<BR>The historical performance of Dr Lal Pathlabs shows a consistent growth trajectory in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Dr Lal Pathlabs has demonstrated robust growth in net sales, rising from 1,203.40 Cr in March 2019 to 2,461.40 Cr in March 2025. The total operating income followed a similar upward trend, reaching 2,461.40 Cr in March 2025, up from 1,203.40 Cr in March 2019. Operating profit, excluding other income, also increased significantly, from 343.60 Cr in March 2020 to 695.50 Cr in March 2025. The profit before tax saw a substantial rise from 300.60 Cr in March 2019 to 624.70 Cr in March 2025, while profit after tax increased from 200.50 Cr to 492.20 Cr in the same period. The company's earnings per share (EPS) improved markedly from 23.91 in March 2019 to 58.27 in March 2025, reflecting enhanced profitability. On the balance sheet, total assets grew from 1,351.46 Cr in March 2020 to 2,630.17 Cr in March 2025, while total liabilities rose from 1,351.46 Cr to 2,630.17 Cr, indicating a proportional increase in both assets and liabilities. Cash flow from operating activities also showed improvement, increasing from 283.00 Cr in March 2020 to 568.00 Cr in March 2025, although the net cash outflow was recorded at -68.00 Cr in March 2025. Overall, Dr Lal Pathlabs has shown a strong performance with consistent growth in sales, profits, and assets over the years.

Is Dr Lal Pathlabs technically bullish or bearish?

As of December 1, 2025, the trend is mildly bullish, supported by daily moving averages, though caution is advised due to mixed signals from weekly indicators.

As of 1 December 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by the daily moving averages indicating a bullish trend. However, the weekly MACD and Bollinger Bands are both mildly bearish, suggesting some caution in the short term. The monthly indicators, including MACD and Bollinger Bands, are bullish, indicating a stronger long-term outlook. Overall, while there are mixed signals, the prevailing trend is mildly bullish, driven primarily by daily moving averages.

Are Dr Lal Pathlabs Ltd latest results good or bad?

Dr. Lal PathLabs Ltd's latest Q3 FY26 results show a net profit increase of 16.41% and revenue growth of 10.66%, indicating solid operational performance. However, the stock is considered overvalued with a high P/E ratio of 44x, leading analysts to rate it as a "SELL" due to concerns about sustainability amidst increasing competition.

Dr. Lal PathLabs Ltd's latest results for Q3 FY26 indicate a mixed performance. On the positive side, the company reported a net profit of ₹150.40 crores, which reflects a year-on-year increase of 16.41%. Additionally, revenue grew by 10.66% year-on-year to ₹730.60 crores, marking the seventh consecutive quarter of revenue growth. The operating margin remained steady at 30.67%, and the PAT margin improved to 20.83%, up 102 basis points from the previous year.<BR><BR>However, despite these positive metrics, the company's valuation appears stretched, trading at a significant P/E ratio of 44x, which is considered "very expensive." Analysts have rated the stock as a "SELL" based on a proprietary score of 37 out of 100, indicating concerns about the sustainability of its current valuation amidst moderating growth rates and increasing competition in the diagnostics sector.<BR><BR>In summary, while the operational performance shows solid fundamentals, the high valuation and recent technical trends suggest caution for potential investors.

Has Dr Lal Pathlabs Ltd declared dividend?

Yes, Dr Lal Pathlabs Ltd has declared a dividend of 35% (₹7 per share) with an ex-date of February 5, 2026. The company has shown positive total returns over the past 2 to 5 years, despite recent short-term declines.

Dr Lal Pathlabs Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 35%<BR>- Amount per share: 7<BR>- Ex-date: 05 Feb 26<BR><BR>Dividend Yield: 0.91%.<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -7.73%, the dividend return was 0.65%, resulting in a total return of -7.08%.<BR><BR>Over the past 6 months, the price return was -7.94%, the dividend return was 1.03%, leading to a total return of -6.91%.<BR><BR>In the last year, the price return was -1.01%, the dividend return was 1.61%, culminating in a total return of 0.6%.<BR><BR>Over the past 2 years, the price return was 15.29%, the dividend return was 4.76%, resulting in a total return of 20.05%.<BR><BR>In the last 3 years, the price return was 38.36%, the dividend return was 6.56%, leading to a total return of 44.92%.<BR><BR>Over the past 4 years, the price return was 1.02%, the dividend return was 5.75%, culminating in a total return of 6.77%.<BR><BR>In the last 5 years, the price return was 26.82%, the dividend return was 7.75%, resulting in a total return of 34.57%.<BR><BR>Overall, Dr Lal Pathlabs Ltd has declared a significant dividend and has shown positive total returns over longer periods, particularly in the 2 to 5-year ranges, indicating a favorable performance for investors.

Should I buy, sell or hold Dr Lal Pathlabs Ltd?

Why is Dr Lal Pathlabs Ltd falling/rising?

As of 07-May, Dr Lal Pathlabs Ltd's stock price is at 1,566.65, down 1.26%. Despite this decline, the stock has shown strong historical performance and increased investor interest, indicating that the recent drop may be temporary.

As of 07-May, Dr Lal Pathlabs Ltd's stock price is currently at 1,566.65, reflecting a decrease of 20.0 points or 1.26%. Despite this decline, the stock has shown strong performance over various time periods, with a 14.51% increase over the past week and a 14.71% rise over the past month, significantly outperforming the Sensex, which increased by only 1.21% and 4.33% respectively during the same periods.<BR><BR>Today's trading session saw the stock reach an intraday high of Rs 1620, indicating some upward momentum earlier in the day, but it also experienced a low of Rs 1542.95, contributing to the overall decline. The stock has been trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a generally positive trend despite the current drop.<BR><BR>Investor participation has increased, with a delivery volume of 4.49 lacs on 06 May, which is up by 3.78% compared to the 5-day average. This indicates a growing interest among investors, although the stock underperformed its sector by 2.93% today.<BR><BR>The company benefits from high management efficiency, being net-debt free, and having substantial institutional holdings at 38.57%, which typically indicates confidence from more knowledgeable investors. Additionally, Dr Lal Pathlabs has consistently outperformed the broader market over the long term, generating a 9.95% return over the past year and a remarkable 60.97% over the past three years.<BR><BR>In summary, while the stock is currently experiencing a decline, its strong historical performance, increased investor participation, and solid fundamentals suggest that the recent drop may be a temporary fluctuation rather than a sign of underlying weakness.

Which are the latest news on Dr Lal Pathlabs?